Mi a CohBar, Inc. (CWBR piaci tőkésítése)

CohBar, Inc. piaci tőkésítése (CWBR) $1.08M

CohBar, Inc. (CWBR) Egy Részvényre Jutó Nyereség

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.

Év	EPS	Változtassa meg
2026 (TTM)	$-4.32	4.60%
2022	$-4.13	-40.49%
2021	$-6.94	-22.80%
2020	$-8.99	-5.96%
2019	$-9.56	-16.29%
2018	$-11.42	45.11%
2017	$-7.87	43.09%
2016	$-5.50	51.52%
2015	$-3.63	17.86%
2014	$-3.08	51.72%
2013	$-2.03	-44.38%
2012	$-3.65	0.00%

Év

EPS

Változtassa meg

2026 (TTM)

$-4.32

4.60%

2022

$-4.13

-40.49%

2021

$-6.94

-22.80%

2020

$-8.99

-5.96%

2019

$-9.56

-16.29%

2018

$-11.42

45.11%

2017

$-7.87

43.09%

2016

$-5.50

51.52%

2015

$-3.63

17.86%

2014

$-3.08

51.72%

2013

$-2.03

-44.38%

2012

$-3.65

0.00%

Vállalat	EPS	EPS különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-500.93%	US
Argenx SE ARGX.US	$27.74	-742.13%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-417.13%	BE

Vállalat

EPS

EPS különbség

Ország